Immunovant
Manufacturing · New York, United States · 201-500 Employees
View Company Info for Free
Overview
Headquarters
320 W 37th St Rm 6, New York, New York, ...Phone Number
(917) 580-3099Website
www.immunovant.comRevenue
-Stock Symbol
IMVTIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Immunovant
Immunovant, Inc. is a clinical-stage biopharmaceutical company dedicated to enabling normal lives for people with autoimmune diseases. As a leader in FcRn inhibitor technology, we are boldly developing innovative therapies for a range of debilitating autoimmune diseases with significant unmet patient needs. Our investigational compound, batoclimab, is a novel, fully human, monoclonal antibody targeting the neonatal Fc receptor (FcRn).Explore more
Immunovant Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Immunovant your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Immunovant had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Immunovant recently announced quarterly report
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Immunovant has new funding data
Product Launch: Get notified when Immunovant launches new products
Congratulate Masked Content for being promoted to Masked Content at Immunovant
Check out if Immunovant is spiking on competitors!
Immunovant, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Immunovant has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to Immunovant
Compare insights from companies similar to Immunovant, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Immunovant is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Immunovant is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Immunovant.
Immunovant financials insights
Gather financial insights about Immunovant, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Stock Offering
$200M
2021
Corporate Investment
$200M
2025
Share Placement
$450M
Immunovant Tech Stack
A closer look at the technologies used by Immunovant
Most Recent Scoops
Open Position
Open Position
Open Position
Open Position
Open Position
Immunovant News & Media
Immunovant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026
DURHAM, N.C., July 23, 2026 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT) today announced that it will report its financial results for the first quarter ended June 30, 2026 on Thursday, August 6, 2026 before the market opens. Roivant Sciences Ltd. (ROIV), Immunovant’s majority stockholder, will host a live conference call and webcast at 8:00 a.m. ET that same day, which will include a business update for Immunovant.Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026
DURHAM, N.C., May 20, 2026 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported corporate updates and financial results for its fourth quarter and fiscal year ended March 31, 2026.Immunovant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026, and Provide Business Update on Wednesday, May 20, 2026
DURHAM, N.C., May 11, 2026 (GLOBE NEWSWIRE) -- Immunovant (Nasdaq: IMVT) today announced that it will report its financial results for the fourth quarter and fiscal year ended March 31, 2026, and provide a business update at 8:00 a.m. ET on Wednesday, May 20, 2026.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding Immunovant
Sign Up For FreeTo access detailed company insights
Immunovant, Inc. is a clinical-stage biopharmaceutical company dedicated to enabling normal lives for people with autoimmune diseases. As a leader in FcRn inhibitor technology, we are boldly developing innovative therapies for a range of debilitating autoimmune diseases with significant unmet patient needs. Our investigational compound, batoclimab,... Read More
